AKRO vs. PTGX, MORF, DVAX, XNCR, DAWN, TARO, KNSA, KURA, RCUS, and ANIP
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Protagonist Therapeutics (PTGX), Morphic (MORF), Dynavax Technologies (DVAX), Xencor (XNCR), Day One Biopharmaceuticals (DAWN), Taro Pharmaceutical Industries (TARO), Kiniksa Pharmaceuticals (KNSA), Kura Oncology (KURA), Arcus Biosciences (RCUS), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Akero Therapeutics (NASDAQ:AKRO) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
Protagonist Therapeutics has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protagonist Therapeutics received 162 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 61.49% of users gave Akero Therapeutics an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
Akero Therapeutics presently has a consensus price target of $41.13, indicating a potential upside of 106.45%. Protagonist Therapeutics has a consensus price target of $38.00, indicating a potential upside of 23.62%. Given Akero Therapeutics' higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Protagonist Therapeutics.
Akero Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.
98.6% of Protagonist Therapeutics shares are owned by institutional investors. 9.7% of Akero Therapeutics shares are owned by insiders. Comparatively, 5.0% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Protagonist Therapeutics' return on equity of 43.42% beat Akero Therapeutics' return on equity.
In the previous week, Akero Therapeutics had 32 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 41 mentions for Akero Therapeutics and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.70 beat Akero Therapeutics' score of 0.30 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Summary
Protagonist Therapeutics beats Akero Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akero Therapeutics Competitors List
Related Companies and Tools
